Assessment of albumin removal from an immunoaffinity spin column: Critical implications for proteomic examination of the albuminome and albumin-depleted samples

Rebekah L. Gundry, Melanie Y. White, Julie Nogee, Irina Tchernyshyov, Jennifer E. Van Eyk

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

High abundance proteins in serum and plasma (e.g., albumin) are routinely removed during proteomic sample processing as they can mask lower abundance proteins and peptides of biological/clinical interest. A common method of albumin depletion is based on immunoaffinity capture, and many immunoaffinity devices are designed for multiple uses. In this case, it is critical that the albumin captured on the affinity matrix is stripped from the column prior to regeneration of the matrix and processing of subsequent samples, to ensure no carryover and that maximal binding sites are available for subsequent samples. The current study examines the ability of a manufacturer's protocol to remove the proteins and peptides captured by an immunoaffinity spin column. The data presented in the current work illustrate the difficulty in completely removing albumin from the immunoaffinity device, and consequently, may explain the variability and decreased efficiency shown for this device in previous studies. In summary, the current data present important considerations for the implementation of multiple-use immunoaffinity devices for processing subsequent clinical samples in a proteomic workflow.

Original languageEnglish (US)
Pages (from-to)2021-2028
Number of pages8
JournalProteomics
Volume9
Issue number7
DOIs
StatePublished - Apr 1 2009

Fingerprint

Proteomics
Albumins
Equipment and Supplies
Processing
Peptides
Proteins
Workflow
Masks
Serum Albumin
Blood Proteins
Regeneration
Binding Sites
Plasmas

Keywords

  • Albumin
  • Antihuman serum albumin column
  • Serum

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Assessment of albumin removal from an immunoaffinity spin column : Critical implications for proteomic examination of the albuminome and albumin-depleted samples. / Gundry, Rebekah L.; White, Melanie Y.; Nogee, Julie; Tchernyshyov, Irina; Van Eyk, Jennifer E.

In: Proteomics, Vol. 9, No. 7, 01.04.2009, p. 2021-2028.

Research output: Contribution to journalArticle

Gundry, Rebekah L. ; White, Melanie Y. ; Nogee, Julie ; Tchernyshyov, Irina ; Van Eyk, Jennifer E. / Assessment of albumin removal from an immunoaffinity spin column : Critical implications for proteomic examination of the albuminome and albumin-depleted samples. In: Proteomics. 2009 ; Vol. 9, No. 7. pp. 2021-2028.
@article{ddcbf147b658450b8f574bdc69200be3,
title = "Assessment of albumin removal from an immunoaffinity spin column: Critical implications for proteomic examination of the albuminome and albumin-depleted samples",
abstract = "High abundance proteins in serum and plasma (e.g., albumin) are routinely removed during proteomic sample processing as they can mask lower abundance proteins and peptides of biological/clinical interest. A common method of albumin depletion is based on immunoaffinity capture, and many immunoaffinity devices are designed for multiple uses. In this case, it is critical that the albumin captured on the affinity matrix is stripped from the column prior to regeneration of the matrix and processing of subsequent samples, to ensure no carryover and that maximal binding sites are available for subsequent samples. The current study examines the ability of a manufacturer's protocol to remove the proteins and peptides captured by an immunoaffinity spin column. The data presented in the current work illustrate the difficulty in completely removing albumin from the immunoaffinity device, and consequently, may explain the variability and decreased efficiency shown for this device in previous studies. In summary, the current data present important considerations for the implementation of multiple-use immunoaffinity devices for processing subsequent clinical samples in a proteomic workflow.",
keywords = "Albumin, Antihuman serum albumin column, Serum",
author = "Gundry, {Rebekah L.} and White, {Melanie Y.} and Julie Nogee and Irina Tchernyshyov and {Van Eyk}, {Jennifer E.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1002/pmic.200800686",
language = "English (US)",
volume = "9",
pages = "2021--2028",
journal = "Proteomics",
issn = "1615-9853",
publisher = "Wiley-VCH Verlag",
number = "7",

}

TY - JOUR

T1 - Assessment of albumin removal from an immunoaffinity spin column

T2 - Critical implications for proteomic examination of the albuminome and albumin-depleted samples

AU - Gundry, Rebekah L.

AU - White, Melanie Y.

AU - Nogee, Julie

AU - Tchernyshyov, Irina

AU - Van Eyk, Jennifer E.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - High abundance proteins in serum and plasma (e.g., albumin) are routinely removed during proteomic sample processing as they can mask lower abundance proteins and peptides of biological/clinical interest. A common method of albumin depletion is based on immunoaffinity capture, and many immunoaffinity devices are designed for multiple uses. In this case, it is critical that the albumin captured on the affinity matrix is stripped from the column prior to regeneration of the matrix and processing of subsequent samples, to ensure no carryover and that maximal binding sites are available for subsequent samples. The current study examines the ability of a manufacturer's protocol to remove the proteins and peptides captured by an immunoaffinity spin column. The data presented in the current work illustrate the difficulty in completely removing albumin from the immunoaffinity device, and consequently, may explain the variability and decreased efficiency shown for this device in previous studies. In summary, the current data present important considerations for the implementation of multiple-use immunoaffinity devices for processing subsequent clinical samples in a proteomic workflow.

AB - High abundance proteins in serum and plasma (e.g., albumin) are routinely removed during proteomic sample processing as they can mask lower abundance proteins and peptides of biological/clinical interest. A common method of albumin depletion is based on immunoaffinity capture, and many immunoaffinity devices are designed for multiple uses. In this case, it is critical that the albumin captured on the affinity matrix is stripped from the column prior to regeneration of the matrix and processing of subsequent samples, to ensure no carryover and that maximal binding sites are available for subsequent samples. The current study examines the ability of a manufacturer's protocol to remove the proteins and peptides captured by an immunoaffinity spin column. The data presented in the current work illustrate the difficulty in completely removing albumin from the immunoaffinity device, and consequently, may explain the variability and decreased efficiency shown for this device in previous studies. In summary, the current data present important considerations for the implementation of multiple-use immunoaffinity devices for processing subsequent clinical samples in a proteomic workflow.

KW - Albumin

KW - Antihuman serum albumin column

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=65349176461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349176461&partnerID=8YFLogxK

U2 - 10.1002/pmic.200800686

DO - 10.1002/pmic.200800686

M3 - Article

C2 - 19294703

AN - SCOPUS:65349176461

VL - 9

SP - 2021

EP - 2028

JO - Proteomics

JF - Proteomics

SN - 1615-9853

IS - 7

ER -